Paper Details

  1. Home
  2. Paper Details

Practical considerations in the management of inhaled prostacyclin therapy for pulmonary hypertension associated with interstitial lung disease (WHO group 3).

Author: HamlynJoan, LeeCharlie, PorcelliJulie, SchmitAnn

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Inhaled treprostinil (Tyvaso) has been approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). This review provides practical considerations for optimizing the management of PH-ILD patients, including patient education, monitoring, titration methods, and mitigation of side effects.
Paper Details　
Original Abstract of the Article :
Pulmonary hypertension (PH), as a consequence of lung disease or hypoxia, has been classified as Group 3 PH by the World Symposium on Pulmonary Hypertension. The most common lung diseases associated with Group 3 PH are chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD)....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.rmed.2022.106806

データ提供：米国国立医学図書館（NLM）

Inhaled Prostacyclin: A Beacon of Hope for Pulmonary Hypertension Associated with Interstitial Lung Disease

Pulmonary hypertension (PH) associated with interstitial lung disease (ILD), known as WHO Group 3 PH, can feel like a relentless desert storm, making it difficult to breathe. This article delves into the practical considerations of inhaled prostacyclin therapy for PH-ILD, offering guidance for healthcare professionals navigating this challenging terrain. The article highlights the efficacy of inhaled treprostinil (Tyvaso) in improving clinical outcomes for patients with PH-ILD, while also addressing potential side effects and strategies for optimization.

Finding Relief in the Storm

The article underscores the importance of inhaled prostacyclin therapy in improving the lives of patients with PH-ILD. The study's findings demonstrate the effectiveness of inhaled treprostinil in reducing symptoms, improving exercise capacity, and enhancing quality of life. This therapy offers a beacon of hope in the desert storm of PH-ILD, providing a path toward improved breathing and a better quality of life.

Navigating the Side Effects

The article also highlights the importance of addressing potential side effects associated with inhaled prostacyclin therapy. By understanding the potential risks and implementing appropriate strategies for mitigation, healthcare professionals can ensure the safety and efficacy of treatment. This research serves as a reminder that even in the midst of a relentless desert storm, with careful navigation and the right tools, we can find ways to weather the challenges and improve patient outcomes.

Dr. Camel's Conclusion

This article provides valuable insights for healthcare professionals managing PH-ILD, offering practical guidance for optimizing inhaled prostacyclin therapy and improving patient outcomes. The research underscores the importance of finding a balance between efficacy and safety, ensuring that patients receive the benefits of treatment while minimizing potential side effects.

Date :
  1. Date Completed 2022-04-26
  2. Date Revised 2022-05-25
Further Info :

Pubmed ID

35334313

DOI: Digital Object Identifier

10.1016/j.rmed.2022.106806

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.